Ponatinib
Ponatinib-1501
Phase 2 small_molecule terminated
Quick answer
Ponatinib for Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL) is a Phase 2 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated